Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.

Novalić Z, Verkuijlen SAWM, Verlaan M, Eersels JLH, de Greeuw I, Molthoff CFM, Middeldorp JM, Greijer AE.

J Med Virol. 2017 Dec;89(12):2207-2216. doi: 10.1002/jmv.24870. Epub 2017 Aug 29.

2.

Quantitative multi-target RNA profiling in Epstein-Barr virus infected tumor cells.

Greijer AE, Ramayanti O, Verkuijlen SA, Novalić Z, Juwana H, Middeldorp JM.

J Virol Methods. 2017 Mar;241:24-33. doi: 10.1016/j.jviromet.2016.12.007. Epub 2016 Dec 16.

3.

Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.

Ramayanti O, Juwana H, Verkuijlen SA, Adham M, Pegtel MD, Greijer AE, Middeldorp JM.

Int J Cancer. 2017 Jan 1;140(1):149-162. doi: 10.1002/ijc.30418. Epub 2016 Sep 23.

4.

Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.

Stoker SD, Wildeman MA, Novalic Z, Fles R, van der Noort V, de Bree R, Braunius WW, van den Broek GB, Kreike B, Kross KW, Juwana H, Ramayanti O, Verkuijlen SA, de Boer JP, Greijer AE, Middeldorp JM, Tan IB.

Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1557-67. doi: 10.1007/s00405-015-3620-y. Epub 2015 May 1.

PMID:
25929413
5.

Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Stoker SD, Novalić Z, Wildeman MA, Huitema AD, Verkuijlen SA, Juwana H, Greijer AE, Tan IB, Middeldorp JM, de Boer JP.

J Cancer Res Clin Oncol. 2015 Oct;141(10):1845-57. doi: 10.1007/s00432-015-1969-3. Epub 2015 Apr 29.

PMID:
25920375
6.

Current status of cancer care for young patients with nasopharyngeal carcinoma in Jakarta, Indonesia.

Adham M, Stoker SD, Wildeman MA, Rachmadi L, Gondhowiardjo S, Atmakusumah D, Gatot D, Fles R, Greijer AE, Hermani B, Middeldorp JM, Tan IB.

PLoS One. 2014 Jul 14;9(7):e102353. doi: 10.1371/journal.pone.0102353. eCollection 2014.

7.

BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator.

Hoebe EK, Le Large TY, Greijer AE, Middeldorp JM.

Rev Med Virol. 2013 Nov;23(6):367-83. doi: 10.1002/rmv.1758. Epub 2013 Aug 31. Review.

8.

Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment.

Adham M, Greijer AE, Verkuijlen SA, Juwana H, Fleig S, Rachmadi L, Malik O, Kurniawan AN, Roezin A, Gondhowiardjo S, Atmakusumah D, Stevens SJ, Hermani B, Tan IB, Middeldorp JM.

Clin Cancer Res. 2013 Apr 15;19(8):2175-86. doi: 10.1158/1078-0432.CCR-12-2897. Epub 2013 Mar 14.

9.

Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.

Greijer AE, Stevens SJ, Verkuijlen SA, Juwana H, Fleig SC, Verschuuren EA, Hepkema BG, Cornelissen JJ, Brooimans RA, Verdonck LF, Middeldorp JM.

Clin Dev Immunol. 2012;2012:543085. doi: 10.1155/2012/543085. Epub 2012 Dec 30.

10.

Epstein-Barr virus-encoded BARF1 protein is a decoy receptor for macrophage colony stimulating factor and interferes with macrophage differentiation and activation.

Hoebe EK, Le Large TY, Tarbouriech N, Oosterhoff D, De Gruijl TD, Middeldorp JM, Greijer AE.

Viral Immunol. 2012 Dec;25(6):461-70. doi: 10.1089/vim.2012.0034. Epub 2012 Oct 12.

PMID:
23061794
11.

Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.

Hoebe EK, Wille C, Hopmans ES, Robinson AR, Middeldorp JM, Kenney SC, Greijer AE.

J Virol. 2012 Oct;86(20):11322-32. Epub 2012 Aug 15.

12.

Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.

Wildeman MA, Novalic Z, Verkuijlen SA, Juwana H, Huitema AD, Tan IB, Middeldorp JM, de Boer JP, Greijer AE.

Clin Cancer Res. 2012 Sep 15;18(18):5061-70. doi: 10.1158/1078-0432.CCR-12-0574. Epub 2012 Jul 3.

13.

Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population.

Hutajulu SH, Indrasari SR, Indrawati LP, Harijadi A, Duin S, Haryana SM, Steenbergen RD, Greijer AE, Middeldorp JM.

Mol Cancer. 2011 May 2;10:48. doi: 10.1186/1476-4598-10-48.

14.

Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.

Hoebe EK, Hutajulu SH, van Beek J, Stevens SJ, Paramita DK, Greijer AE, Middeldorp JM.

Clin Vaccine Immunol. 2011 Feb;18(2):298-304. doi: 10.1128/CVI.00193-10. Epub 2010 Dec 1.

15.

Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma.

Hutajulu SH, Hoebe EK, Verkuijlen SA, Fachiroh J, Hariwijanto B, Haryana SM, Stevens SJ, Greijer AE, Middeldorp JM.

Infect Agent Cancer. 2010 Sep 19;5:16. doi: 10.1186/1750-9378-5-16.

16.

Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue.

Benders AA, Tang W, Middeldorp JM, Greijer AE, Thorne LB, Funkhouser WK, Rathmell WK, Gulley ML.

Head Neck Pathol. 2009 Dec;3(4):276-82. doi: 10.1007/s12105-009-0148-8. Epub 2009 Nov 12.

17.

Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum.

Greijer AE, Delis-van Diemen PM, Fijneman RJ, Giles RH, Voest EE, van Hinsbergh VW, Meijer GA.

Virchows Arch. 2008 May;452(5):535-44. doi: 10.1007/s00428-008-0578-9.

18.

c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer.

Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ.

Hum Pathol. 2006 Jun;37(6):668-74.

PMID:
16733206
19.

Mutation analysis of the HIF-1alpha oxygen-dependent degradation domain in invasive breast cancer.

Vleugel MM, Greijer AE, van der Wall E, van Diest PJ.

Cancer Genet Cytogenet. 2005 Dec;163(2):168-72.

PMID:
16337862
20.

Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1).

Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E.

J Pathol. 2005 Jul;206(3):291-304.

PMID:
15906272
21.

Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells.

Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, van der Wall E.

Cell Oncol. 2005;27(1):43-9.

22.

Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.

Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E.

J Clin Pathol. 2005 Feb;58(2):172-7.

23.

The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis.

Greijer AE, van der Wall E.

J Clin Pathol. 2004 Oct;57(10):1009-14. Review.

24.

Lack of lymphangiogenesis during breast carcinogenesis.

Vleugel MM, Bos R, van der Groep P, Greijer AE, Shvarts A, Stel HV, van der Wall E, van Diest PJ.

J Clin Pathol. 2004 Jul;57(7):746-51.

25.

Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related.

Bos R, van Diest PJ, van der Groep P, Shvarts A, Greijer AE, van der Wall E.

Breast Cancer Res. 2004;6(4):R450-9. Epub 2004 Jun 9.

26.

Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha).

Bos R, van Diest PJ, van der Groep P, Greijer AE, Hermsen MA, Heijnen I, Meijer GA, Baak JP, Pinedo HM, van der Wall E, Shvarts A.

Oncogene. 2003 Dec 4;22(55):8948-51.

PMID:
14654791
27.

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.

Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.

Cancer. 2003 Mar 15;97(6):1573-81.

28.

Multiplex real-time NASBA for monitoring expression dynamics of human cytomegalovirus encoded IE1 and pp67 RNA.

Greijer AE, Adriaanse HM, Dekkers CA, Middeldorp JM.

J Clin Virol. 2002 Feb;24(1-2):57-66.

PMID:
11744429
29.

Quantitative competitive NASBA for measuring mRNA expression levels of the immediate early 1, late pp67, and immune evasion genes US3, US6 and US11 in cells infected with human cytomegalovirus.

Greijer AE, Adriaanse HM, Kahl M, Tacken NM, Oldenburg N, Sijlmans A, van de Crommert JM, Dekkers CA, Sillekens PT, Middeldorp JM.

J Virol Methods. 2001 Aug;96(2):133-47.

PMID:
11445144
30.

Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.

Greijer AE, Verschuuren EA, Dekkers CA, Adriaanse HM, van der Bij W, The TH, Middeldorp JM.

J Infect Dis. 2001 Aug 1;184(3):247-55. Epub 2001 Jul 10.

PMID:
11443549
31.

Direct quantification of human cytomegalovirus immediate-early and late mRNA levels in blood of lung transplant recipients by competitive nucleic acid sequence-based amplification.

Greijer AE, Verschuuren EA, Harmsen MC, Dekkers CA, Adriaanse HM, The TH, Middeldorp JM.

J Clin Microbiol. 2001 Jan;39(1):251-9.

32.
33.
34.

Optimized conditions for the production of recombinant amphotropic retroviral vector preparations.

Kaptein LC, Greijer AE, Valerio D, van Beusechem VW.

Gene Ther. 1997 Feb;4(2):172-6.

35.

Intracellular analysis of in vitro modified HIV Tat protein.

Koken SE, Greijer AE, Verhoef K, van Wamel J, Bukrinskaya AG, Berkhout B.

J Biol Chem. 1994 Mar 18;269(11):8366-75.

Supplemental Content

Loading ...
Support Center